How to access Aldurazyme from Egypt, the named-patient import pathway, 2026
Reviewed by the Reserve Meds clinical operations team. Last reviewed: 2026-05-13.
An Egyptian patient with mucopolysaccharidosis I (MPS I, including Hurler, Hurler-Scheie, and moderate-to-severe Scheie forms) may receive a prescription for Aldurazyme (laronidase) from their treating metabolic geneticist. Aldurazyme is FDA-approved in the United States and manufactured by Sanofi Genzyme. It is a recombinant alpha-L-iduronidase enzyme replacement therapy administered by intravenous infusion. Local availability of Aldurazyme in Egypt can be inconsistent: the drug may not be on every specialty pharmacy's standing formulary, the specific indication may not match what is locally registered, or the strength required may be back-ordered. When that happens, a named-patient import pathway through EDA remains a legitimate route for the patient whose physician has already prescribed the drug.
This guide explains the pathway, the documentation your physician needs, typical costs and indicative timing, and where Reserve Meds fits in.
Ask about Aldurazyme in Egypt
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
The clinical situation
Aldurazyme is a recombinant alpha-L-iduronidase enzyme replacement therapy. Mechanism: a recombinant form of human alpha-L-iduronidase that catalyses the hydrolysis of terminal alpha-L-iduronic acid residues in dermatan and heparan sulfate. Dosing: 0.58 mg/kg by intravenous infusion once weekly, with pre-infusion antihistamine and antipyretic premedication, per FDA labeling. Baseline workup per FDA labeling includes urinary GAG baseline, cardiac echocardiogram, pulmonary function where age-appropriate, airway and sleep assessment, and infusion-reaction risk screening. The FDA boxed warning covers anaphylaxis and severe allergic reactions. Other important warnings include anaphylaxis and severe allergic reactions, airway compromise during infusion in patients with sleep apnea or upper airway disease, and concurrent acute febrile or respiratory illness considerations. Your specialist will discuss the risk-benefit profile and schedule monitoring before initiating therapy.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Is Aldurazyme legally importable into Egypt?
Yes, through the Egyptian Drug Authority (EDA) named-patient and personal-use import framework, coordinated with the treating facility's pharmacy. Egypt has an established pathway for specialty medicines approved by reference authorities (US FDA, EMA, MHRA) but not stocked or registered for the specific indication locally.
The EDA named-patient route allows an Egyptian-licensed physician to request import of a medicine when: (a) the medicine is approved by a recognised reference authority, (b) no clinically equivalent locally registered alternative is suitable for the patient's indication and history, (c) the treating physician takes clinical responsibility for use, and (d) chain of custody is documented from the US source to the administering facility. Applications are typically filed through the dispensing institution's import pharmacy on the physician's behalf, with approval issued on a per-patient, per-cycle quantity basis.
How the pathway works, step by step
- Consultation with your treating specialist. The prescribing decision is clinical. Your specialist documents the indication, prior therapies where relevant, and rationale for Aldurazyme.
- Baseline screening. Urinary GAG baseline, cardiac echocardiogram, pulmonary function where age-appropriate, airway and sleep assessment, and infusion-reaction risk screening are confirmed and documented.
- EDA named-patient application. Your specialist or the facility's import pharmacy files the application with clinical rationale, patient reference, product strength, quantity requested, and chain-of-custody plan.
- US-side sourcing. Reserve Meds coordinates with our US-licensed pharmaceutical wholesale partner to secure product from Sanofi Genzyme's authorised distribution under DSCSA chain-of-custody.
- Cold-chain shipment. Aldurazyme requires refrigerated transport at 2 to 8 degrees Celsius. Shipments include temperature-monitored packaging with continuous loggers and tamper-evident seals.
- Arrival and first dose. The dispensing pharmacy releases product against the physician's prescription, and your specialist initiates therapy.
What documentation your physician needs
Your physician will typically need to provide:
- A clinical rationale letter confirming diagnosis, prior therapies where relevant, and Aldurazyme as the indicated next step
- Verification of their Egyptian medical licence
- A patient identifier, anonymised reference where privacy is preferred
- Documented pre-treatment screening consistent with FDA labeling (see above)
- The planned dosing regimen (0.58 mg/kg by intravenous infusion once weekly, with pre-infusion antihistamine and antipyretic premedication, per FDA labeling)
- A monitoring plan covering GAG baselines, airway management plan, and pre-medication protocol
Reserve Meds provides a physician documentation kit tailored for MPS enzyme replacement therapy therapies, including the templates EDA reviewers commonly request.
Typical costs and indicative timing
Reserve Meds gives you a transparent, itemised custom quote at intake. Medicine price: quote on request. You get a written quote for your case before you commit. International logistics, EDA documentation handling, cold-chain shipping, and coordination add incremental cost. The delivered quote we issue at intake shows each line separately.
We give you a written timeline estimate for your case before you commit. Refills ship on a rolling cadence aligned to the dosing schedule.
Where Reserve Meds fits in
Reserve Meds is a US-based digital health company that coordinates access to cross-border specialty medicine. For Aldurazyme specifically, we provide:
- Sourcing. Through our US-licensed pharmaceutical wholesale partner, operating under DSCSA chain-of-custody from manufacturer to export.
- Documentation. Regulatory package tailored for your physician and for EDA review, including MPS enzyme replacement therapy class templates.
- Cold-chain logistics. Temperature-monitored, internationally tracked shipment to your named dispensing facility with continuous temperature loggers.
- Dedicated case lead. A named point of contact for your family and your physician across the full case arc.
We are a coordinator. We are not the prescriber, not a pharmacy, and not a dispensing facility. All clinical decisions remain with your treating specialist, and dispensing sits with the licensed Egyptian pharmacy of record. Reserve Meds operates on cash-pay only and does not bill insurance.
Frequently asked
Is this legal in Egypt? Yes, when executed through the EDA named-patient and personal-use framework with appropriate documentation, clinical rationale, and a licensed dispensing facility. The pathway is routinely used across oncology, rare disease, and immunology at Egyptian tertiary centers.
What about the boxed warning? The FDA boxed warning on Aldurazyme covers anaphylaxis and severe allergic reactions. Your specialist performs the risk-benefit assessment, schedules monitoring, and counsels the patient per labeling. Reserve Meds does not make that clinical judgement, your physician does.
Will my private health insurance cover this? Cash-pay is the default posture. Some Egyptian private insurers reimburse named-patient imports on a case-by-case basis; many patients pay cash. We supply documentation for your submission but do not process insurance claims.
How does cold-chain affect timing? Aldurazyme ships refrigerated. We use validated packaging with continuous temperature monitoring, and arrival temperature data is logged on every shipment.
What if my physician has not filed a named-patient request before? Named-patient import is an institutional process most major Egyptian tertiary centers (Children's Cancer Hospital Egypt 57357, the National Cancer Institute Cairo, and Cairo University teaching hospitals) have encountered. Our documentation kit is written for first-time applicants and tracks what EDA reviewers commonly ask for.
Recent regulatory and access news for Aldurazyme in Egypt
The EDA Notifications and Decisions feed at edaegypt.gov.eg has not posted a Aldurazyme-specific registration notice over the last 12 months as of 2026-06-04. The Egyptian Authority for Unified Procurement (UPA) at upa.gov.eg central procurement bulletins have not added Aldurazyme to the public-sector tender catalogue. Sanofi continues commercial supply of laronidase for mucopolysaccharidosis I; the National Policy for Rare Diseases groupings cover lysosomal storage disorders through accredited Centres of Excellence. We give you a written timeline estimate for your case before you commit. the named-patient route remains the active path through this interval. We update this section on each case file at intake; the snapshot date governs.
Next step
For Aldurazyme coordination in Egypt, start your case at the portal or message us on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.
Composite case examples. This content is for general information and does not constitute medical advice.
Frequently asked questions
How can I get Aldurazyme in Egypt if it is not approved or available there?
Reserve Meds coordinates US-sourced Aldurazyme for patients in Egypt through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for Egypt and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Aldurazyme in Egypt through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Aldurazyme. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in Egypt, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Aldurazyme in Egypt through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Aldurazyme to a patient in Egypt?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Aldurazyme to your treating physician or hospital pharmacy in Egypt, with appropriate handling for the product.
How long does it take, and what does Aldurazyme in Egypt cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Aldurazyme in Egypt?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.